The End of the Road for a HIV Vaccine?
Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government…
Address: 781 Chestnut Ridge Rd, Morgantown, WV 26505,United States of America
Tel: 1-800-RX-MYLAN
Mylan Pharmaceuticals, a subsidiary of Mylan Inc. based in Morgantown, W.Va., is a market leader in researching, developing, manufacturing, marketing and distributing generic pharmaceutical products in a variety of sophisticated dosage forms. Since 1961, Mylan Pharmaceuticals has held a long-standing reputation for quality, integrity and exemplary service and has maintained its commitment to increasing and protecting consumer access to affordable pharmaceuticals.
Mylan Pharmaceuticals has one of the largest product portfolios in the U.S., consisting of more than 200 products. According to IMS Health, one of every 12 prescriptions dispensed in the U.S. is a Mylan product.1 The company pioneered and continues to specialize in groundbreaking delivery technologies and difficult-to-manufacture and -formulate pharmaceuticals that treat diseases ranging from angina to arthritis, depression to diabetes, pain to Parkinson’s disease, and schizophrenia to sleep disorders.
Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government…
Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched…
Manuel Guzman, President of CAS, a division of the American Chemical Society, outlines the organization’s vital role in scientific knowledge management and its commitment to accelerating breakthroughs in biomedical research.…
Regeneron has agreed to pay USD 256 million to acquire at-home DNA test maker 23andMe after the troubled firm declared bankruptcy. Through the buyout, Regeneron will acquire the data of…
2023 may have been a breakthrough year for cell and gene therapies with the FDA approving a record of seven novel treatments, but 2024 did not fall behind in the…
As the search for effective Alzheimer’s treatments continues to evolve, Annovis Bio is taking a distinct approach with buntanetap, a novel oral candidate designed to intervene more broadly in disease…
While on the surface it may look like pharmaceuticals have been spared by Donald Trump’s “Liberation Day” trade policies, drugmakers still lack a clear picture of how they will be…
Peter Marks, the US FDA’s top official for vaccines and cell and gene therapies, has resigned. A survivor of the first Trump administration, when his office faced intense pressure to…
The Alzheimer’s Drug Discovery Foundation (ADDF) operates in the critical niche of translational research, attempting to bridge the “Valley of Death” between discovery and commercialisation using a venture philanthropy model…
Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by…
As healthcare systems grapple with rising costs and the need for broader access to treatment, off-patent medicines have taken on increasing importance. With budgets under pressure and blockbuster drugs losing…
David H. Crean, Ph.D., is a San Diego-based venture capitalist and strategic advisor with over 30 years of experience in life sciences and healthcare. Drawing on a deep personal connection…
See our Cookie Privacy Policy Here
